View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
December 20, 2021updated 11 Jul 2022 2:15pm

Ventura County Hematology Oncology to use Deep Lens’ clinical trial solution

Deep Lens’ AI-based solution automates the process of identifying potentially eligible participants for clinal trials.

Ventura County Hematology Oncology Specialists has signed an agreement to integrate Deep Lens’ clinical trial matching solution which is based on artificial intelligence (AI).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The practice will also use Deep Lens’ other services as part of the collaboration.

Deep Lens’ software will help in identifying eligible participants for clinal trials effectively and quickly.

It automates the process to identify potentially eligible subjects during diagnosis and then match them to relevant clinical trials.

The AI-based solution will pre-screen the participants from EMR (OncoEMR) of Ventura County Hematology Oncology Specialists and merge the molecular data feeds from Foundation Medicine, Guardant Health, and all pathology feeds for automatic identification of qualified participants for the clinical trials.

Deep Lens sales provider and vice-president Tyrone Richardson said: “The majority of patients diagnosed with cancer are treated by community oncologists, and it is critical to bring more trials to this setting so that patients can receive access to novel therapies in a comfortable, familiar environment, without having to travel or commute to larger medical centres.

“Ventura is a great example of a community oncology practice that prioritizes clinical research and we’re delighted that we can add value to their program and help more of their patients receive stellar, cutting- edge care.”

The company stated that its pre-screening and clinical trial matching solution is provided to oncology practices for free.

Recently, Deep Lens launched its new Real Time Feasibility tool designed to identify eligible patients and select the efficient study sites in the Deep Lens Unity Network for cancer clinical trials.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena